4.0 Article

Estimating the impact of expanded access to antiretroviral therapy on maternal, paternal and double orphans in sub-Saharan Africa, 2009-2020

Journal

AIDS RESEARCH AND THERAPY
Volume 8, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/1742-6405-8-13

Keywords

-

Funding

  1. Canadian Institutes for Health Research
  2. National Institutes of Health
  3. Canadian Institutes of Health Research
  4. Health Canada
  5. Agouron Pharmaceuticals Inc
  6. Boehringer Ingelheim Pharmaceuticals Inc
  7. Bristol-Myers Squibb
  8. GlaxoSmithKline
  9. Merck Frosst Laboratories
  10. Abbott
  11. Argos Therapeutics
  12. Bioject Inc
  13. Boehringer Ingelheim
  14. BMS
  15. Gilead Sciences
  16. Hoffmann-La Roche
  17. Janssen-Ortho
  18. Merck Frosst
  19. Pfizer
  20. Schering
  21. Serono Inc
  22. TheraTechnologies
  23. Tibotec
  24. Trimeris
  25. NATIONAL INSTITUTE ON DRUG ABUSE [DP1DA026182] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Background: HIV/AIDS has orphaned 11.6 million children in sub-Saharan Africa. Expanded antiretroviral therapy (ART) use may reduce AIDS orphanhood by decreasing adult mortality and population-level HIV transmission. Methods: We modeled two scenarios to measure the impact of adult ART use on the incidence of orphanhood in 10 sub-Saharan African countries, from 2009 to 2020. Demographic model data inputs were obtained from cohort studies, UNAIDS, UN Population Division, WHO and the US Census Bureau. Results: Compared to current rates of ART uptake, universal ART access averted 4.37 million more AIDS orphans by year 2020, including 3.15 million maternal, 1.89 million paternal and 0.75 million double orphans. The number of AIDS orphans averted was highest in South Africa (901.71 thousand) and Nigeria (839.01 thousand), and lowest in Zimbabwe (86.96 thousand) and Cote d'Ivoire (109.12 thousand). Conclusion: Universal ART use may significantly reduce orphanhood in sub-Saharan Africa.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available